Compare Quest Diagnostics Inc (DGX) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Invesco S&P 500 Momentum ETF trades at $152.89. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals.
| DGX | SPMO | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $161.66 |
52-Week Low | $166.42 | $107.84 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SPMO trades at $149.73, down 2.61% today, with a neutral technical signal. The ETF maintains a bullish moving average trend but faces resistance near $150. Recent news highlights strong momentum performance, gaining 7.5% in June 2026, driven by concentrated technology exposure and AI beneficiaries. A dividend of $0.25 is scheduled for June 2026.
Outlook remains positive with AI-driven growth potential, but risks include high volatility from sector concentration. Analyst sentiment is mixed, with some recommending buys for momentum exposure. Key support is at $149, with upside resistance at $151-$153.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
